Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper-Reference-Cited by-同舟云学术

Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper

Published:2021-08-14 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Walsh Jennifer¹,Schaufelberger Daniel²,Iurian Sonia³,Klein Sandra⁴,Batchelor Hannah⁵,Turner Roy⁶,Gizurarson Sveinbjörn⁷,Boltri Luigi⁸,Alessandrini Elisa⁹,Tuleu Catherine⁹^ORCID

Affiliation:

1. BioCity Nottingham Jenny Walsh Consulting Ltd Nottingham UK

2. School of Medicine, All Children's Hospital Schaufelberger Consulting LLC and Johns Hopkins University St. Petersburg FL USA

3. Department of Pharmaceutical Technology and Biopharmacy Iuliu Haţieganu University of Medicine and Pharmacy Cluj‐Napoca Romania

4. Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology University of Greifswald Greifswald Germany

5. Strathclyde Institute of Pharmacy and Biomedical Sciences University of Strathclyde Glasgow UK

6. Idorsia Pharmaceuticals Ltd Allschwil Switzerland

7. Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland; and Pharmacy Department Kamuzu University of Health Sciences Blantyre Malawi

8. Pharmaceutical Development Adare Pharmaceuticals Milan Italy

9. University College London School of Pharmacy London UK

Funder

Horizon 2020 Framework Programme

European Commission

Innovative Medicines Initiative

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14989

Reference108 articles.

1. European Medicines Agency (EMA).Examples of key binding elements in the PIP decisions. EMA/174403/2013 Human Medicines Development and Evaluation. Published 2013.https://www.ema.europa.eu/en/documents/other/examples-key-binding-elements-paediatric-investigation-plan-decisions_en.pdf. Accessed March 12 2021.

2. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007

3. World Health Organisation Unitaid.Innovative Delivery Systems for Paediatric Medicines: Technology Landscape. Published online 2020.https://unitaid.org/assets/Innovative-delivery-systems-for-paediatric-medicines-technology-landscape.pdf

4. European Medicines Agency (EMA).Evidence of harm from off‐label or unlicensed medicines in children EMEA/126327/2004. Published 2004.https://www.ema.europa.eu/en/documents/other/evidence-harm-label-unlicensed-medicines-children_en.pdf. Accessed March 12 2021.

5. How to ensure the quality and safety of unlicensed oral medicines;Lowey A;Pharm J,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unmet technological demands in orodispersible films for age-appropriate paediatric drug delivery;Drug Delivery and Translational Research;2023-11-13

2. Paediatric medicine issues and gaps from healthcare workers point of view: survey results and a narrative review from the global accelerator for paediatric formulations project;Frontiers in Pharmacology;2023-07-17

3. Responsive Sensory Evaluation to Develop Flexible Taste-Masked Paediatric Primaquine Tablets against Malaria for Low-Resource Settings;Pharmaceutics;2023-07-04

4. Development of a new age-appropriate, chewable tablet of mebendazole 500 mg for preventive chemotherapy of soil-transmitted helminth infections in pre-school and school-age children;European Journal of Pharmaceutics and Biopharmaceutics;2023-07

5. Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations;Pharmaceutics;2022-08-03